HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1437 PHI-101 PHI-101 is an orally active, potent third-generation inhibitor of FLT3 that overcomes resistance to multiple drug-resistant mutations. It has potential for research in relapsed or refractory acute myeloid leukemia (AML). Jun 23 2024
E1751 MSC-4381 MSC-4381 (MCT4-IN-1) is an orally active, selective inhibitor of monocarboxylate transporter 4 (MCT4) with an IC50 of 77 nM and a Ki of 11 nM. It has the potential to inhibit lactate efflux and promote intracellular lactate accumulation in MCT4-expressing cell lines. Jun 23 2024
E4607 Oseltamivir acid Oseltamivir acid(GS 4071,Ro 64-0802,Oseltamivir carboxylate), a metabolite of the antiviral compound oseltamivir, acts as a competitive inhibitor of influenza neuraminidases A and influenza neuraminidases B with IC50 of 0.1 to 4.9 nM respectively, thereby preventing virus budding and release. Jun 23 2024
E4594 Lithium iodide hydrate Lithium iodide hydrate is a reagent and the water-crystallized form of lithium iodide. It is commonly used as an electrolyte additive in dye-sensitized solar cells and Li-S batteries, enhancing their cycle life. Jun 23 2024
E4606 Dihexa Dihexa(PNB-0408), an oligopeptide drug, is an orally active and blood-brain barrier-permeable analog of angiotensin IV. It binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at its receptor, c-Met. Dihexa can also be used as a therapeutic potential in the treatment of Alzheimer’s disease. Jun 19 2024
E1917 SLF1081851 hydrochloride SLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation. Jun 18 2024
E1528 RP-6685 RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models. Jun 18 2024
E1912 B102(PARP/HDAC-IN-1) B102(PARP/HDAC-IN-1) is a dual inhibitor of PARP and HDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces DNA damage and apoptosis in vitro. Jun 17 2024
E1980 Atogepant Atogepant(MK-8031, AGN-241689) is a potent, selective, orally available antagonist of the calcitonin gene-related peptide (CGRP) receptor, with ki of 0.026 nM for human CGRP receptor. It is used for the preventive treatment episodic migraine. Jun 17 2024
E1788 CQ211 CQ211 is a cell penetrant, potent and selective inhibitor of RIOK2(Right open reading frame kinase 2) with a Kd of 6.1 nM. It effectively inhibits cancer cell proliferation and shows promising in vivo efficacy in mouse xenograft models. Jun 13 2024
E1894 PROTAC tubulin-Degrader-1(compound W13) PROTAC tubulin-Degrader-1(compound W13) is an inhibitor of PROTAC tubulin exhibiting antitumor activity against human lung cancer. Jun 11 2024
P1239 ADH-1 ADH-1, an antagonist of N-cadherin, blocks N-cadherin-mediated cell adhesion. It exhibits significant antitumor activity against N-cadherin-expressing cells in vitro assays. Jun 10 2024
E1949 DuP-697 DuP-697 is a potent, irreversible, selective, and orally active inhibitor of COX-2 with an IC50 value of 10 nM for human COX-2, respectively. DuP-697 exerts antiproliferative, antiangiogenic, and apoptotic effects in colorectal cancer cells. Jun 10 2024
E1662 Elenestinib phosphate Elenestinib phosphate(BLU-263 phosphate) is a potent and orally active inhibitor of tyrosine kinase that exhibits potent inhibition of c-KIT (D816V) mutation. BLU-263 phosphate has the potential for its use in the research of systemic mastocytosis (SM). Jun 10 2024
E1908 HRO761 HRO761 is a potent, selective, allosteric inhibitor of Werner syndrome RecQ helicase (WRN). It binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation, and demonstrates anti-proliferative effects specifically in microsatellite instability (MSI) cancer cells. Jun 10 2024
E4596 GSK-2879552 GSK-2879552 is a selective and potent inhibitor of Lysine-specific demethylase 1 (LSD1, KDM1A), with the potential to treat Small cell lung cancer (SCLC). It induces the expression of putative KDM1A target genes and demonstrates potent, predominantly cytostatic, antiproliferative activity in SCLC cell lines and tumor xenograft models. Jun 07 2024
E4595 SB-743921 SB-743921 (SB-921) is an inhibitor of Kinesin Spindle Protein (KSP), a mitotic protein essential for cell cycle control and motility. It functions by selectively targeting rapidly dividing cells and disrupting spindle formation during cell division, leading to G2/M phase arrest and ultimately causing cell death. It also inhibits proliferation and induces apoptosis in diffuse large B-cell lymphoma (DLBCL) cell lines. Jun 07 2024
S7512 GSK269962A GSK269962A is a potent and selective inhibitor of ROCK with IC50 values of 1.6 nM for ROCK1 and 4 nM for ROCK2. It shows potential as an alternative treatment for overactive bladder (OAB), and also exhibits anti-inflammatory and vasodilatory activities. Jun 06 2024
S9894 Vafidemstat Vafidemstat(ORY-2001) is a potent, selective, brain-penetrant dual inhibitor of lysine-specific histone demethylase (LSD1, KDM1A) and MAO-B, with IC50 values of 105 nM and 58 nM, respectively. It shows potential for treating memory deficits and behavioral alterations in neurodegenerative and psychiatric diseases. Jun 06 2024
E4593 Benzo-15-crown-5 ether Benzo-15-crown-5-ether (B15C5) is employed as a ligand in metal-catalyzed reactions to improve reactivity and selectivity by coordinating with metal cations. Additionally, it serves as a chelating agent for sodium and potassium ions. Jun 06 2024